Atara Biotherape Stock Price, News & Analysis

Atara Biotherapeutics (NASDAQ: ATRA) announced the grant of 126,928 restricted stock units and stock options for newly hired employees, totaling 186,378 shares. These awards were approved by the Compensation Committee and are part of Atara's 2018 Inducement Plan, effective June 1, 2022. The restricted stock units will vest over four years, while the stock options have a ten-year term with an exercise price of $4.83 per share. This action complies with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new talent while supporting the company’s growth in T-cell immunotherapy.

Atara Biotherapeutics (NASDAQ: ATRA) announced that Bayer intends to terminate their exclusive worldwide licensing agreement for next-gen mesothelin-directed CAR T-cell therapies, including ATA3271 and ATA2271, aimed at high mesothelin-expressing tumors. This follows Bayer's strategic review prioritizing its pipeline. Atara will regain rights to continue clinical development and commercialization of the therapies and will proceed with ongoing studies, including a Phase 1 trial for ATA2271, even as patient enrollment is paused temporarily. The company will postpone the IND filing for ATA3271 beyond Q4 2022 while maintaining cash runway guidance into Q4 2023.

Atara Biotherapeutics (NASDAQ: ATRA) announced the approval of 115,059 restricted stock units and 118,745 stock options for newly hired employees. This grant took place on May 2, 2022, under their 2018 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units will vest over four years, while the stock options have a ten-year term with an exercise price of $6.94 per share. This strategic move aims to attract talent as Atara develops therapies for serious diseases utilizing its T-cell immunotherapy platform.

Atara Biotherapeutics (ATRA) reported strong progress in Q1 2022, with an upcoming interim analysis of ATA188 for progressive multiple sclerosis scheduled for June. Financial highlights include a cash balance of $301.8 million as of March 31, 2022, sufficient to fund operations into Q4 2023, bolstered by a $100 million sale of a cell therapy manufacturing facility. Notably, tab-cel's review by the EMA is on track for EC approval in Q4 2022, while Atara advances partnerships and clinical trials for its innovative therapies.

Atara Biotherapeutics (NASDAQ: ATRA) has granted inducement awards to its new Executive Vice President and Chief Technical Officer, Charlene Banard. The awards include 155,350 restricted stock units, time-based stock options for 292,023 shares, and performance-based options for 33,184 shares, all effective as of April 25, 2022. The vesting of these options is contingent on Banard’s continued employment and achieving certain performance goals. The exercise price for the stock options is set at $7.29 per share, equal to the stock's closing price on the grant date.

Atara Biotherapeutics, Inc. (NASDAQ: ATRA) will release its Q1 2022 financial results on May 5, 2022, after market close. A live conference call will follow at 4:30 p.m. EDT to discuss the results and provide a corporate update. Atara is a leader in T-cell immunotherapy, utilizing its unique allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for cancer and autoimmune diseases. The company is advancing its pipeline, notably with tab-cel®, in Phase 3 clinical development for EBV+ PTLD.

Atara Biotherapeutics, Inc. (NASDAQ: ATRA), a leader in T-cell immunotherapy, announced the grant of inducement awards to Brian Robinson, its new Senior Vice President of Global Medical Affairs. The awards include 73,449 restricted stock units and stock options to purchase 138,067 shares, with a performance-based component for an additional 15,689 shares. These awards are part of Atara’s 2018 Inducement Plan, effective April 18, 2022. All stock options have an exercise price of $7.73 per share, reflecting the closing price on the grant date.

Atara Biotherapeutics has granted 37,538 restricted stock units to five newly hired employees as part of its 2018 Inducement Plan, approved by the Compensation Committee of its Board of Directors. The awards, announced on April 1, 2022, vest over four years, incentivizing employee retention. This initiative aligns with Nasdaq Listing Rule 5635(c)(4), highlighting Atara's commitment to employee engagement as it advances its T-cell immunotherapy platform to develop therapies for cancer and autoimmune diseases.

Atara Biotherapeutics (NASDAQ: ATRA) announces the appointment of Charlene Banard as Chief Technical Officer. Banard will oversee process science, quality, and manufacturing. CEO Pascal Touchon highlighted her extensive experience in advanced therapies, including CAR T. Previously, Banard served at Novartis and Shire, where she managed global quality and advanced product pipelines. Atara is known for its innovative T-cell immunotherapies targeting serious diseases, with its lead program in Phase 3 clinical development for EBV-driven conditions.